Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook ® , LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms .
Patent and License Information: standardbio.com/legal/notices .
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

LAB
The Conversation (0)
Peruvian Metals Announces New High-Grade Au-Ag Results at Palta Dorada

Peruvian Metals Announces New High-Grade Au-Ag Results at Palta Dorada

Peruvian Metals Corp (TSXV: PER,OTC:DUVNF) (OTC Pink: DUVNF) ("Peruvian Metals" or the "Company") is pleased to announce new high-grade Gold ("Au") and Silver ("Ag") results from the main San Juan Vein taken on the Au-Ag exposed in the underground workings on its 100% owned Palta Dorada... Keep Reading...
Brixton Metals Reports 97.0% Gold Recovery in Initial Metallurgical Work from the Trapper Gold Target

Brixton Metals Reports 97.0% Gold Recovery in Initial Metallurgical Work from the Trapper Gold Target

Drills 7.50 m of 5.02 g/t Gold, Including 0.50 m of 18.55 g/t Gold, in Hole THN26-393 and 54.00 m of 1.09 g/t Gold and 0.50 m of 37.10 g/t Gold in Hole THN26-394 Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to announce initial metallurgical... Keep Reading...
GoldInxs Commences Maiden Drill Program at the Fishpot Project, Testing Multiple Gold-Silver and Copper-Gold Targets

GoldInxs Commences Maiden Drill Program at the Fishpot Project, Testing Multiple Gold-Silver and Copper-Gold Targets

GoldInxs Mining Corp. ("GoldInxs," or the "Company") (TSXV: INXS, OTCQB: INXGF) is pleased to announce that drilling is underway at its flagship Fishpot Project in Central British Columbia as part of the inaugural drill program intended to test priority targets developed through the convergence... Keep Reading...
RENFORTH INTERSECTS BROAD NICKEL-COBALT AND ZINC-COPPER-SILVER MINERALIZATION IN VICTORIA UNDERCUT DRILLING, INCLUDING 118.0 m OF 0.081% Ni AND 10.9 m OF 0.544% Zn

RENFORTH INTERSECTS BROAD NICKEL-COBALT AND ZINC-COPPER-SILVER MINERALIZATION IN VICTORIA UNDERCUT DRILLING, INCLUDING 118.0 m OF 0.081% Ni AND 10.9 m OF 0.544% Zn

Renforth Resources Inc. (CSE: RFR,OTC:RFHRF | OTC: RFHRF | FSE: 9RR) ("Renforth" or the "Company") is pleased to update shareholders on drill results from its wholly owned Victoria polymetallic nickel deposit in Québec, where 3 drillholes (1,011 m total drilled length) were completed in July... Keep Reading...
Renforth Successfully Intersects Gold in Both Drillholes Undercutting Surface Gold Results within the 2025 MRE Pit Shell at Wholly Owned Parbec Gold Deposit in Malartic, Quebec

Renforth Successfully Intersects Gold in Both Drillholes Undercutting Surface Gold Results within the 2025 MRE Pit Shell at Wholly Owned Parbec Gold Deposit in Malartic, Quebec

(TheNewswire) 15.68 g/t Au over 0.85m from 262.85m to 263.7m in PAR-26-149 is the highest single sample result in the program, located within the open pit shell 9.41 g/t Au over 4.05m from 130.75m to 134.8m in PAR-26-150 is the highest grade-thickness result (38.1 g/t Au x m) in the program,... Keep Reading...
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is... Keep Reading...
Lexaria Announces Results From Animal Study GLP-1-A26-1

Lexaria Announces Results From Animal Study GLP-1-A26-1

(TheNewswire) Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC October 15, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following... Keep Reading...
Lexaria Announces Results from Animal Study GLP-1-A26-1

Lexaria Announces Results from Animal Study GLP-1-A26-1

KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation... Keep Reading...
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.Lexaria's DehydraTECHâ„¢ technology is currently being evaluated both by Lexaria and... Keep Reading...
BriaCell Therapeutics (TSX:BCT)

BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials

BriaCell Therapeutics’ (TSX:BCT,NASDAQ:BCTX) Phase 3 Bria-ABC study has been included in a roundup of breast cancer clinical trials currently enrolling in the US, published by cancer publication CURE.In its September 24 article, CURE enumerated seven studies spanning early-stage to heavily... Keep Reading...
Lexaria Updates Financial Position

Lexaria Updates Financial Position

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax... Keep Reading...

Interactive Chart

Latest Press Releases

Related News